Matt Campbell MD, MS
@DocMattCampbell
I am a genitorurinary medical oncologist at UT MD Anderson. I specialize in kidney, urothelial, adrenal and testicular cancer. all opinions are mine.
First trial of PD1/VEGF bispecific in #kidneycancer just activated today and is @NazliDizman’s trial design project during her @MDAndersonNews heme/onc fellowship 🤓 👉 clinicaltrials.gov/study/NCT06940… @brian_rini @montypal @OncHahn @OAlhalabiMD @DocMattCampbell @ChadTangMD @SGoswamiMDPhD
In our latest podcast, John Heymach from @MDAndersonNews reviews exciting PD1/VEGF bispecific data from the lung cancer. We review the data and discuss applications to GU malignancies. creators.spotify.com/pod/show/the-u…
Tremendously enjoyed working with @Shounak_Gupta et al on this contemporary update of #RenalMedullaryCarcinoma pathology, pathophysiology, differential diagnosis & management. #kidneycancer #rarecancers #endRMC
Here is an update on medullary RCC. Thank you @PavlosMsaouel for your tremendous contribution to this article and thanks to @MichelleDunno17 for the invitation Open access at: journals.sagepub.com/doi/full/10.32…
Surreal to be completing training in oncology, 14 years after beginning the journey as a freshman in college diagnosed with testicular cancer. I owe so much to my doctors, Dr. Ahmed and Dr. Einhorn, who showed me what it meant to treat patients (and people) with compassion
👇Latest treatment & research updates on #RenalMedullaryCarcinoma. #endRMC #RareCancers #kidneycancer
RMC is one of the most aggressive and rare forms of #KidneyCancer. In our latest video, @PavlosMsaouel shares updates on how specialized treatments are improving outcomes for RMC patients. Explore the full Rare Subtypes playlist here: bit.ly/RareSubtypes #AcceleratingCures
White Coat Ceremony for my upcoming Internal Medicine Residency at Baylor College of Medicine @BCM_InternalMed - so grateful and blessed! 🙏
We have a couple of years before she gets to making her own videos advocating for #RCC 🧡. Thanks for all you do @KidneyCancer 👏🏻👏🏻
Thanks Parker for being the tiniest, mightiest advocate! @Sid423
🎉 One of our FAVORITE events of the year, moving for 81’ in beautiful Hermann Park #Houston for the KCA’s 81K Fundraising Challenge! Thank you @DocMattCampbell for leading our #BoneMets Team @MDAndersonNews; KCA leadership @GEVaughan1 & team for organizing this event!
⭐ Join the 2025 KCA Challenge: 81K Strong! ⭐ charity.pledgeit.org/2025Challenge Why 81K? Nearly 81,000 people will be diagnosed with kidney cancer this year. How does it work? Get creative, choose an 81-themed activity, and be part of the change today! #KCAChallenge
Great start to the weekend with @KidneyCancer 81K Houston walk with @MDAndersonNews in honor of those who will diagnosed with kidney cancer this year. Appreciate everyone who came out and walked in the heat @mjmoussa_ @ED_PhD_ @PavlosMsaouel and the bone mets lab.
🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s4158… I’m so thrilled🥳to share our work out now🚨@Nature…
@CYJiangMD is doing some impressive work on MTAP loss in bladder cancer. Come check it out. @MDAndersonNews #ASCO25 #endcancer
Proud of our hem/onc fellow @CYJiangMD (comentored with @IamLinghua and #JJGao) advancing our understanding on #MTAPloss in #bladdercancer. We describe tropism to the lung and hypothesize signaling through TGFb/SMAD3.
Such an honor to receive the Conquer Cancer – Nizar M. Tannir, MD, Endowed Merit Award and to share this moment with Dr. Tannir himself at #ASCO25. Grateful for the support of early-career researchers and thankful to my mentor @montypal and senior author @NazliDizmanMD.
Dear Colleagues, an honor to introduce our colleague @mzugman of @cityofhope Discussing his poster at #ASCO25 on Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC) #KidneyCancer…
🙌Congrats to my terrific friend @CYJiangMD (soon-to-be faculty @MDAndersonNews) for leading this🌟 study on 9p21-loss in mUC, driving worse survival & + lung mets, likely via ↑ TGFβ-EMT signaling. Ongoing preclinical data in CDKN2A-MTAP DKO mice from our amazing #JJGao's lab…
Proud of our hem/onc fellow @CYJiangMD (comentored with @IamLinghua and #JJGao) advancing our understanding on #MTAPloss in #bladdercancer. We describe tropism to the lung and hypothesize signaling through TGFb/SMAD3.
A truly beautiful, patient centered discussion from Dr. #JackieBrown breaking the platinum ceiling in #bladdercancer - future of SG & there may be some cures in metastatic disease for pts on EV-pembro. @ASCO #ASCO25
📢 #ASCO25 | Discussion | Breaking the Platinum Ceiling in Advanced Bladder Cancer | Jacqueline T. Brown, MD—synthesizing Abstracts 4500–4502: cis‑ineligible mUC safety/comparative outcomes (G3–4 47% vs 76%; 8 toxicity‑related deaths) ; Avelumab + SG vs Avelumab PFS…
Excellent and comprehensive discussion by @jackiebrown_MD at the Oral abstract session @ASCO #ASCO25
🌟 DOUBLING of OS for adding encorafenib + cetuximab to FOLFOX in frontline treatment for (MSS) BRAF V600E mCRC!! ‼️ Providers should be testing for BRAF V600E mutations ASAP upon diagnosis of met CRC to identify pts who may benefit from this regimen!! 🙏 Grateful to be a…
Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results: nej.md/3ScDaWC
Great activity of sacituzumab govitecan with pembro in MIBC - @AndreaNecchi showing 44% clinical CR rate and majority patients had bladder preservation! @ASCO #ASCO25
Neoadjuvant Sacituzumab govitecan + Pembrolizumab in MIBC @AndreaNecchi 44% cCR rate 💥 74% bladder preserved without chemoRT 🧬 Luminal subtype may drive response Bladder-sparing path with immuno-ADC combo? Worth watching. #ASCO25 #cancer #oncology @oncoalert @ASCO…
It has Beech a great honor to receive the 2025 @women_in_cancer Mentor of the Year Award! 👩🏻⚕️🇲🇽🦀🌍👨🏻🎓#ASCO2025 Thanks to the mentees @PaolaVS94 @EvelynBeas2 @FersRivera @INCMNSZ_Uronco & institution that made this possible @INCMNSZ_Ensena @incmnszmx @OncoAlert @RobertodelaPea6
Say hi to our fourth 2025 Mentor of the Year Nominee, Dr. Maria Teresa Bourlon de los Ríos, Medical Oncologist at @incmnszmx 🌟Celebrating her steadfast dedication, leadership, and powerful mentorship — a true embodiment of excellence in medicine #MentorOfTheYear @BourlonMaite
Congrats @TiansterZhang on sharing the the latest #PDIGREE info at #ASCO25! Fascinating content - more on that soon - but also the scope of development & participation over time, since 2014!! Grateful for all you do for patients and on KCA’s med steering committee!
Thank you to every one of our 1111 patients who enrolled on #PDIGREE & trust us with the data. We're only just getting started and could not have fully enrolled w/out support from @KidneyCancer @kcCURE @ASCO & many other advocacy groups. #ASCO25 @OncoAlert 7/n